RxDoctor Payments Data

Sherry Miller

Family · Goodlettsville, TNNPI 1194048413

Payments from drug & device makers

$1,008in general payments, 2019–2025

Across 55 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$266
  • Lilly USA, LLC$150
  • AbbVie$119
  • AstraZeneca$104
  • Astellas Pharma US Inc$101
  • GSK$90
  • plus $180 from 8 others

What the payments were for

  • Food & beverage$1,008100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,008 in reported general payments places this provider in the 65th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$35,714
Medicare patients
151
Services billed
783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol66$53,600
OzempicSemaglutide38$45,094
JardianceEmpagliflozin47$43,166
EliquisApixaban23$31,877
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$21,240
XareltoRivaroxaban15$20,991
TrulicityDulaglutide17$16,172
Tresiba Flextouch U-200Insulin Degludec11$13,129
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$10,177
Synjardy XrEmpagliflozin/Metformin Hcl12$9,452
Xigduo XrDapaglifloz Propaned/Metformin11$6,806
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$5,908
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$4,767
Breo ElliptaFluticasone/Vilanterol11$4,378
Incruse ElliptaUmeclidinium Bromide12$4,182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$104$63,77779 claims
Novo NordiskOzempic$266$45,09438 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$90$29,80045 claims
Johnson & JohnsonXarelto$21$20,99115 claims
Lilly USA, LLCTrulicity$150$16,17217 claims
AbbVieSynthroid$119$86415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,706 family providers in Tennessee.

Other family in Goodlettsville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →